Article

Patients With End-Stage Renal Disease, Atrial Fibrillation Have Unique Considerations When Starting Anticoagulation Therapy

Assessing stroke benefit and net clinical benefit of anticoagulation is essential in patients with end-stage renal disease and atrial fibrillation.

In an interview with Pharmacy Times, Zachary Noel, PharmD, BCCP, discussed the presentation at the American Society of Health-System Pharmacists 2021 Midyear Meeting titled "Direct Oral Anticoagulant Dilemmas: Stroke Prevention for Atrial Fibrillation in the Oldest Old and Patients with End-Stage Renal Disease."

In the interview, Noel discussed specific considerations for patients with end-stage renal disease and atrial fibrillation, recommendations for anticoagulation initiation, and how to best assess stroke risk in these populations.

Related Videos
Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule - Image credit: vchalup | stock.adobe.com